SinoMab BioScience Limited

3681

HK0000544194

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:39:05 07/06/2024 pm IST			5-day change	1st Jan Change
1.74 ^HKD	0.00%		-6.45%	+3.57%

25/03	SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
07/02	SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	CI

SinoMab BioScience Limited Reports Earnings Results for the Half Year Ended June 30, 2022

August 22, 2022 at 07:08 pm IST

SinoMab BioScience Limited reported earnings results for the half year ended June 30, 2022. For the half year, the company reported net loss was CNY 143.79 million compared to CNY 114.4 million a year ago. Basic loss per share from continuing operations was CNY 0.15 compared to CNY 0.11 a year ago.

Latest news about SinoMab BioScience Limited

SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	25/03	CI
SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	07/02	CI
SinoMab BioScience Raises HK$62.2 Million from Thirteen Share Subscriptions	15/01	MT
SinoMab BioScience Issues 56.8 Million Shares to 15 Investors	15/12	MT
SinoMab Doses First Batch of Subjects in Phase 1 Trial of Atopic Dermatitis Drug in China	28/11	MT
SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China	27/11	CI
China Accepts Clinical Trial Application for SinoMab BioScience's Alzheimer's Treatment; Shares Rise 3%	16/11	MT
Sinomab Bioscience Limited Announces IND Application for SM03 (Suciraslimab) for the Treatment of Alzheimer's Disease Accepted by NMPA CDE	15/11	CI
China Accepts New Drug Application of SinoMab's Dermatitis Medication; Shares Rise 3%	12/23/12	MT
Sinomab Bioscience Limited announces Change of Non-Executive Directors	06/23/06	CI
Chinese Regulator Accepts License Application for SinoMab's Arthritis Drug	05/23/05	MT
China Accepts SinoMab's Biologics License Application for Arthritis Treatment	05/23/05	MT
SinoMab BioScience Limited Announces National Medical Products Administration Accepts Biologics License Application for SM03 in the Treatment of Rheumatoid Arthritis	05/23/05	CI
SinoMab Bioscience to Shrink Loss in H1	22/23/22	MT
SinoMab BioScience Limited Reports Earnings Results for the Half Year Ended June 30, 2023	21/23/21	CI
SinoMab Bioscience Obtains Clinical Trial Approval in China for Asthma Drug	15/23/15	MT
Sinomab Bioscience Limited Announces IND Approval for Sm17 by Nmpa	14/23/14	CI
Sinomab Bioscience Limited Announces IND Application for SM17 Accepted by NMPA CDE	12/23/12	CI
Chinese Regulator Accepts SinoMab's Investigational New Drug Application for Asthma Treatment	22/23/22	MT
SinoMab BioScience Limited Announces Filing and Acceptance of Investigational New Drug Application for SM17 by the Center for Drug Evaluation of the National Medical Products Administration of China	22/23/22	CI
SinoMab Bioscience Achieves Primary Endpoints for Phase III Clinical Study of Rheumatoid Arthritis Treatment; Shares Cimb 4%	27/23/27	MT
SinoMab BioScience Limited Announces Phase III Clinical Trial of its Product SM03 (Suciraslimab) Achieves the Primary Endpoint for Rheumatoid Arthritis	26/23/26	CI
SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
SinoMab Bioscience Unit's Rent in Haiyao Industrial Park Rises to 9.4 Million Yuan	02/22/02	MT
Hainan Sinomab Enters into A Supplemental Lease Agreement with Haikou Pharma Pursuant to Which the Annual Rental of the Property	01/22/01	CI

Chart SinoMab BioScience Limited

Duration

Period

More charts

Company Profile

SinoMab BioScience Ltd is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE). The Companyâs product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is developing drugs for the treatment of RA, systemic lupus erythematosus (SLE), asthma, pemphigus, sjogrenâs syndrome (SS) and other immunological diseases.

Sector

Pharmaceuticals

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
SINOMAB BIOSCIENCE LIMITED	+3.57%	243M
CSL LIMITED	+0.82%	91.94B
SAMSUNG BIOLOGICS CO.,LTD.	-1.32%	38.74B
UCB	+64.13%	26.66B
BIOMARIN PHARMACEUTICAL INC.	-16.31%	15.32B
INCYTE CORPORATION	-5.78%	13.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.38%	11.65B
ALTEOGEN INC.	+173.10%	10.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.84%	10.12B
SWEDISH ORPHAN BIOVITRUM AB	+4.19%	9.06B